没食子酸氧钒对STZ诱导的糖尿病小鼠的降糖作用研究
|
摘要
为了探究没食子酸氧钒对STZ诱导的糖尿病小鼠的降糖作用,采用链脲佐菌素(STZ)建立糖尿病小鼠模型。实验动物分为正常组、模型组、阳性组、GAOV高、中、低剂量组以及VOSO_4高、中、低剂量组,造模成功后灌胃28 d,监测糖尿病小鼠饮食量、饮水量、体重和FBG的变化,测定小鼠血清生化指标(UREA、Cr、ALB、ALT)和血脂四项指标(CHO、TG、LDL-C、HDL-C),计算胰腺、肝、肾、脾等脏器指数,采用SPSS19.0分析软件对实验数据进行单因素方差分析。结果显示,与模型组相比,GAOV组小鼠体重、饮食饮水量、FBG及各血清生化指标、血脂四项指标变化均存在显著性差异(P<0.05)。其中,GAOV中剂量组与模型组有极显著性差异(P<0.01),与阳性组无显著性差异(P>0.05)。综上所述,没食子酸氧钒对STZ诱导的糖尿病小鼠有较好的体内降糖活性,且降糖作用起效快、效果好,为糖尿病药物的开发提供了新的方向。
To investigate the hypoglycemic effect of vanadium complexes of gallic acid on STZ-induced diabetic mice, diabetic mice model was established by intraperitoneal injection of streptozocin(STZ).The experimental animals were divided into normal group, model group, positive group, high, medium and low dose GAOV group and stepwise dose VOSO_4 groups. After successful modeling, the mice were given intragastric administration for 28 days, and the changes of diet, water intake, body weight and FBG of diabetic mice were monitored. The serum biochemical parameters(UREA, Cr, ALB, ALT) and four items of blood lipid(CHO, TG, LDL-C, HDL-C) of each group were determined. The indexes of pancreas, liver, kidney and spleen were calculated and the experimental data were analyzed by one-way ANOVA with SPSS19.0 analysis software. The results showed that there were significant differences in the changes of weight, diet, drinking water, FBG, serum biochemical indexes and four indexes of blood lipid in the GAOV group compared with the model group(P<0.05). Among them, there was a significant difference between the GAOV medium dose group and the model group(P<0.01), and there was no significant difference between the GAOV medium group and the positive group(P>0.05). In conlusion, vanadium gallate complex has good hypoglycemic activity in STZ-induced diabetic mice in vivo, and the hypoglycemic effect is fast and effective, which provides a new direction for the development of diabetes drugs.
To investigate the hypoglycemic effect of vanadium complexes of gallic acid on STZ-induced diabetic mice, diabetic mice model was established by intraperitoneal injection of streptozocin(STZ).The experimental animals were divided into normal group, model group, positive group, high, medium and low dose GAOV group and stepwise dose VOSO_4 groups. After successful modeling, the mice were given intragastric administration for 28 days, and the changes of diet, water intake, body weight and FBG of diabetic mice were monitored. The serum biochemical parameters(UREA, Cr, ALB, ALT) and four items of blood lipid(CHO, TG, LDL-C, HDL-C) of each group were determined. The indexes of pancreas, liver, kidney and spleen were calculated and the experimental data were analyzed by one-way ANOVA with SPSS19.0 analysis software. The results showed that there were significant differences in the changes of weight, diet, drinking water, FBG, serum biochemical indexes and four indexes of blood lipid in the GAOV group compared with the model group(P<0.05). Among them, there was a significant difference between the GAOV medium dose group and the model group(P<0.01), and there was no significant difference between the GAOV medium group and the positive group(P>0.05). In conlusion, vanadium gallate complex has good hypoglycemic activity in STZ-induced diabetic mice in vivo, and the hypoglycemic effect is fast and effective, which provides a new direction for the development of diabetes drugs.
引文
[1] 常连举,张宗和,黄嘉玲,等.没食子酸的制备与应用综述 [J].生物质化学工程,2010,44(4):48-52.
[2] 王文慧,王晓玲.老年糖尿病患者口服降糖药物用药依从性的影响因素分析 [J].中国医药导刊,2015,17(6):634-636.
[3] 李海华.酰腙类钒配合物的合成、结构表征及生物活性研究 [D].大连:辽宁师范大学,2013.
[4] 宋晶园.新型钒化合物降血糖作用及其机制的研究 [D].大连:辽宁师范大学,2007.
[5] 王夔.生命科学中的微量元素 [M].北京:中国计量出版社,1996:145-171.
[6] CANTLEY L C,CANTLEY L G,JOSEPHSON L.A characterization of vanadate interactions with the (Na,K)-ATPase,mechanistic and regulatory implications [J].Journal of Biological Chemistry,1978,253(20):7361-7368.
[7] 刘英,宋晶园,邢永恒,等.钒化合物的类胰岛素作用及其机制 [J].生物技术通讯,2008,19(5):769-771.
[8] 杨晓达.抗糖尿病钒化合物:瓶颈和解决思路 [C].2011南湖学术论坛——生物无机化学专题研讨会论文摘要集.嘉兴:2011.
[9] 刘广洋.四种海藻寡糖钒配合物的制备及其生物活性的研究[D].北京:中国科学院大学,2013.
[10] THOMPSON K H,ORVIG C.Vanadium in diabetes:100 years from Phase 0 to Phase I [J].Journal of Inorganic Biochemistry,2006,100(12):1925-1935.
[11] MONGA V,THOMPSON K H,YUEN V G,et al.Vanadium complexes with mixed O,S anionic ligands derived from maltol:synthesis,characterization,and biological studies [J].Inorganic Chemistry,2005,44(8):2678-2688.
[12] MONGA U,KERRIGAN A J,THORNBY J,et al.Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy [J].Journal of Rehabilitation Research & Development,2005,42(3):391-399.
[13] 董雅琼,牛霞,肖茹月,等.钒配合物的药理作用和理性药物设计 [J].中国科学:化学,2017(2):52-61.
[14] 廖家荣,甘勇军,严明志,等.罗格列酮氧钒配合物的合成及表征 [J].中国药房,2011,22(45):4253-4255.
[15] 余洁,兰云军,沈晓军.没食子酸与锆离子的相互作用及其鞣制性能研究 [J].中国皮革,2014,43(19):11-16.
[16] 汪莹莹.没食子酸、并没食子酸的分离、性能及应用研究 [D].合肥:安徽大学,2012.
[17] 张红艳.钒化合物的合成、表征及其性质研究 [D].福州:福州大学,2004.
[18] 陆新.高脂血症中医病因病机及辨证治疗研究概况 [J].浙江中医杂志,2010,45(4):304-305.
[19] 曾平原.高血压及糖尿病早期肾损害患者尿液中微量清蛋白检测分析 [J].检验医学与临床,2010,7(9):779-780.
[20] 张泽生,秦程广,李雨蒙.D-松醇对STZ诱导2型糖尿病小鼠肝损伤的干预作用 [J].中国食品添加剂,2016(12):109-114.
[21] MCNEILL J H,YUEN V G,DAI S,et al.Increased potency of vanadium using organic ligands [J].Molecular and Cellular Biochemistry,1995,153(1-2):175-180.
[22] DUAN L Y,YE J W,SUN W L,et al.A novel PTP1b inhibitor vanadium-flavone complex:synthesis and pharmacodynamic evaluation in streptozotocin-induced diabetic mice [J].Medicinal Chemistry Research,2017,26(9):1863-1870.
[23] HUANG D W,CHANG W C ,WU J S,et al.Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet [J].Nutrition Research,2016,36(2):150-160.
[24] 木艾塔尔·努尔麦麦提,夏木西努尔·艾克拜尔,吐尼沙汗·买提卡斯木.维药中没食子酸的药理作用研究进展 [J].中国民族医药杂志,2015,21(11):53-54.
[2] 王文慧,王晓玲.老年糖尿病患者口服降糖药物用药依从性的影响因素分析 [J].中国医药导刊,2015,17(6):634-636.
[3] 李海华.酰腙类钒配合物的合成、结构表征及生物活性研究 [D].大连:辽宁师范大学,2013.
[4] 宋晶园.新型钒化合物降血糖作用及其机制的研究 [D].大连:辽宁师范大学,2007.
[5] 王夔.生命科学中的微量元素 [M].北京:中国计量出版社,1996:145-171.
[6] CANTLEY L C,CANTLEY L G,JOSEPHSON L.A characterization of vanadate interactions with the (Na,K)-ATPase,mechanistic and regulatory implications [J].Journal of Biological Chemistry,1978,253(20):7361-7368.
[7] 刘英,宋晶园,邢永恒,等.钒化合物的类胰岛素作用及其机制 [J].生物技术通讯,2008,19(5):769-771.
[8] 杨晓达.抗糖尿病钒化合物:瓶颈和解决思路 [C].2011南湖学术论坛——生物无机化学专题研讨会论文摘要集.嘉兴:2011.
[9] 刘广洋.四种海藻寡糖钒配合物的制备及其生物活性的研究[D].北京:中国科学院大学,2013.
[10] THOMPSON K H,ORVIG C.Vanadium in diabetes:100 years from Phase 0 to Phase I [J].Journal of Inorganic Biochemistry,2006,100(12):1925-1935.
[11] MONGA V,THOMPSON K H,YUEN V G,et al.Vanadium complexes with mixed O,S anionic ligands derived from maltol:synthesis,characterization,and biological studies [J].Inorganic Chemistry,2005,44(8):2678-2688.
[12] MONGA U,KERRIGAN A J,THORNBY J,et al.Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy [J].Journal of Rehabilitation Research & Development,2005,42(3):391-399.
[13] 董雅琼,牛霞,肖茹月,等.钒配合物的药理作用和理性药物设计 [J].中国科学:化学,2017(2):52-61.
[14] 廖家荣,甘勇军,严明志,等.罗格列酮氧钒配合物的合成及表征 [J].中国药房,2011,22(45):4253-4255.
[15] 余洁,兰云军,沈晓军.没食子酸与锆离子的相互作用及其鞣制性能研究 [J].中国皮革,2014,43(19):11-16.
[16] 汪莹莹.没食子酸、并没食子酸的分离、性能及应用研究 [D].合肥:安徽大学,2012.
[17] 张红艳.钒化合物的合成、表征及其性质研究 [D].福州:福州大学,2004.
[18] 陆新.高脂血症中医病因病机及辨证治疗研究概况 [J].浙江中医杂志,2010,45(4):304-305.
[19] 曾平原.高血压及糖尿病早期肾损害患者尿液中微量清蛋白检测分析 [J].检验医学与临床,2010,7(9):779-780.
[20] 张泽生,秦程广,李雨蒙.D-松醇对STZ诱导2型糖尿病小鼠肝损伤的干预作用 [J].中国食品添加剂,2016(12):109-114.
[21] MCNEILL J H,YUEN V G,DAI S,et al.Increased potency of vanadium using organic ligands [J].Molecular and Cellular Biochemistry,1995,153(1-2):175-180.
[22] DUAN L Y,YE J W,SUN W L,et al.A novel PTP1b inhibitor vanadium-flavone complex:synthesis and pharmacodynamic evaluation in streptozotocin-induced diabetic mice [J].Medicinal Chemistry Research,2017,26(9):1863-1870.
[23] HUANG D W,CHANG W C ,WU J S,et al.Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet [J].Nutrition Research,2016,36(2):150-160.
[24] 木艾塔尔·努尔麦麦提,夏木西努尔·艾克拜尔,吐尼沙汗·买提卡斯木.维药中没食子酸的药理作用研究进展 [J].中国民族医药杂志,2015,21(11):53-54.